Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Investigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process
Subject has first degree family member with a known hereditary coagulopathy.
Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Subjects must not be or have an immediate family member (spouse, parent, legal guardian, sibling or child) who is an investigational site sponsor or staff directly involved with the trial, unless IRB approval is granted previously
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor-investigator staff directly involved with this trial, unless prospective Institutional Review Board [IRB] approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Patients who are investigational site staff members directly involved in the conduct of the trial, and their family members, site staff members otherwise supervised by the investigator, or patients who are Archigen employees directly involved in the conduct of the trial.
History of Wilsons disease or family member with Wilsons disease
History of hemochromatosis or family member with hemochromatosis
Patient has at least one medically fit family member expected to be HLA mismatched at -/ more commonly and preferred: -/ loci (e.g. parent, sibling, niece/nephew, etc. but adult children preferred)
Is or has an immediate family member (example, spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
Is or has an immediate family member (spouse or children) who is investigational site or staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Participant is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is an investigational site or sponsor-investigator staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is granted allowing exception to this criterion for a specific subject
Is or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this study, unless prospective institutional review board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Assignment of DPA to a family member or guardian should be offered to all patients  years of age or older
Immediate family member who is investigational site or sponsor staff directly involved with this study
Participant is or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific participant.
Patient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial without prospective Institutional Review Board approval (by chair or designee) is given
Family relative or close friend is a trial staff member or a study participant
Melan-A (MART)  or solute carrier family , member  (SLCA) (+) staining results; (if patients have not had staining test in the past, the test will be run after patient consent is obtained, but before enrollment)
Employees of the clinical study site who are directly involved with the conduct of the study, or immediate family members of such individuals. These subjects may be treated at another site participating in the study
Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Pfizer employees directly involved in the conduct of the trial.
Participant is a family member or employee of the investigator
Participant is a family member or employee of the investigator
Subject is a family member or employee of the investigator
INCLUSION CRITERIA - HPC-A CELL DONOR: Family member (first degree relatives)
Patient is a staff member of the sponsor or clinical site and is involved in the conduct of the study or the relative of such a staff member. Patient Exclusion Criteria - Part :
Patient is a staff member of the sponsor or clinical site and is involved in the conduct of the study or the relative of such a staff member
Participant is a family member or employee of the investigator
Colorectal adenocarcinoma patients must be known to have CpG island methylator phenotype; CIMP-high phenotype will be defined as hypermethylation at  or more of the  methylation-specific polymerase chain reaction (PCR) markers (mutL homolog , colon cancer, nonpolyposis type  [hMLH], cyclin-dependent kinase inhibitor A [P], cyclin-dependent kinase  associated protein  [P], amyloid beta (A) precursor protein-binding, family A, member  [MINT], amyloid beta (A) precursor protein-binding, family A, member  [MINT], and amyloid beta (A) precursor protein-binding, family A, member  [MINT])
Subjects who are part of the staff personnel directly involved with this study
Subjects who are family members of the investigational study staff
No other household member or relative participating in the study
Patient has a spouse/partner other or close family member who he/she defines as the primary caregiver
Patient has a family member or close friend eligible and interested in participating in the study
Workshop A ( -  weeks- City of Hope)\r\n* Either one of the following:\r\n* City of Hope (COH) cancer patient (all types and at any time point of their disease) OR\r\n* Caretaker/friend family member of the cancer patient
The triad will be ineligible if any member lives in the home less than % of the time
If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
CAREGIVERS: Family member or friend of an eligible patient.
Caregiver inclusion criteria:\r\n* Adults (>= )\r\n* Family member or friend of an eligible patient
Have a co-survivor (friend or family member) willing to participate in this research study
DCG: Is an adult family member (at least  years old) of a patient with an advanced-stage cancer
Subject is able to perform home drainage of the pleural effusion or has sufficient resources (family member, caregiver, home health)
PATIENTS: Willing to identify a FCG (immediate or extended family member) to participate
PATIENT: Have a family member or friend eligible and interested in participating in the MODEL Care study
FAMILY CAREGIVER: Chosen by a family member or friend with cancer to join them in participating in the MODEL Care study
Has another family member already enrolled in ICCAN (as determined by patient report)
Informal Caregivers will be accrued using the following inclusion criteria:\r\n* The primary informal caregiver as identified by patients participating in the study; this refers to either a family member or friend who will be providing the majority of care following surgery\r\n* Able to read and understand English
INCLUSION CRITERIA FOR PATIENTS: Agrees to family member (family member; significant other; friend) participation in study and to selecting the individual who could participate
INFORMAL CAREGIVERS: The primary informal caregiver as identified by patients participating in the study; this refers to either a family member or friend who will be providing the majority of care following surgery
PILOT II (FAMILY MEMBER): Female and male biological and non-biological family members of BRCA-positive individuals OR Lynch syndrome positive individuals
Family member of the investigation study staff
Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.
Is or has an immediate family member who is investigational site or sponsor staff directly involved with this study
Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).
Inclusion:\n\n          -   years of age or older\n\n          -  Have a cancer diagnosis\n\n          -  Self identify as African American\n\n          -  Therapeutic Phase I, II or III clinical trial at Massey Cancer Center (regardless of\n             whether or not they join the therapeutic trial)\n\n          -  Be able to provide informed consent\n\n          -  We will also recruit one family member/caregiver (N = ) of each participating\n             patient\n\n          -  Consented patients will not be excluded from this study if their family member\n             declines to participate by completing the Cancer Communication Assessment Tool for\n             Families (CCAT-F).
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. Is or has an immediate family member (e.g. spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
